ArticleNature communications2022

Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy.

Junmeng Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.